Atai Life Sciences Balance Sheet Health
Financial Health criteria checks 4/6
Atai Life Sciences has a total shareholder equity of $146.3M and total debt of $25.1M, which brings its debt-to-equity ratio to 17.2%. Its total assets and total liabilities are $197.5M and $51.2M respectively.
Key information
17.2%
Debt to equity ratio
US$25.14m
Debt
| Interest coverage ratio | n/a |
| Cash | US$85.92m |
| Equity | US$146.32m |
| Total liabilities | US$51.20m |
| Total assets | US$197.52m |
Recent financial health updates
Is Atai Life Sciences (NASDAQ:ATAI) Using Debt In A Risky Way?
Jul 15
Is Atai Life Sciences (NASDAQ:ATAI) Using Debt Sensibly?
Mar 02We're Hopeful That Atai Life Sciences (NASDAQ:ATAI) Will Use Its Cash Wisely
Aug 07We're Hopeful That Atai Life Sciences (NASDAQ:ATAI) Will Use Its Cash Wisely
Apr 22Recent updates
Psychedelic Stock Deep Dive: Atai Life Sciences
Sep 03Is Atai Life Sciences (NASDAQ:ATAI) Using Debt In A Risky Way?
Jul 15ATAI: Enormous Potential Upside But No Clarity Yet
May 27Is Atai Life Sciences (NASDAQ:ATAI) Using Debt Sensibly?
Mar 02atai Life Sciences achieves positive results in phase 1 trial of kratom-derived drug
Oct 12Atai Life Sciences: Decentralized Drug Discovery Platform
Oct 06ATAI Life Sciences GAAP EPS of -$0.24 misses by $0.01
Aug 15We're Hopeful That Atai Life Sciences (NASDAQ:ATAI) Will Use Its Cash Wisely
Aug 07Atai Life Sciences: Leading But Early Stage Psychedelic Therapeutics Developer
Jul 07atai Life Sciences company Kures Therapeutics appoints Dr. Chad Beyer as CEO
Jun 30Atai Life Sciences N.V.: A First Take
Jun 02Atai Life Sciences And The Future Of Psychedelics For Mental Health
May 27We're Hopeful That Atai Life Sciences (NASDAQ:ATAI) Will Use Its Cash Wisely
Apr 22Financial Position Analysis
Short Term Liabilities: ATAI's short term assets ($114.1M) exceed its short term liabilities ($19.6M).
Long Term Liabilities: ATAI's short term assets ($114.1M) exceed its long term liabilities ($31.6M).
Debt to Equity History and Analysis
Debt Level: ATAI has more cash than its total debt.
Reducing Debt: Insufficient data to determine if ATAI's debt to equity ratio has reduced over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ATAI has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: ATAI has less than a year of cash runway if free cash flow continues to reduce at historical rates of 26% each year
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/22 23:51 |
| End of Day Share Price | 2025/01/22 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Atai Life Sciences N.V. is covered by 13 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Leonildo Delgado | Baader Helvea Equity Research |
| Sumant Satchidanand Kulkarni | Canaccord Genuity |
| Charles Duncan | Cantor Fitzgerald & Co. |